Eli Lilly's Blowout Comes With a Price Tag: +53% Volume, -15% Price, and a Raise That Locks a Flat Q4

Lilly's own decomposition is the story. Worldwide revenue grew 39% on 53% volume growth, partially offset by a 15% decline in realized prices. The United States is the manageable version, with volume up 41% and price down 7%. Outside the US it is a different business: volume grew 76% while price fell 29%.

The deceleration matters more than the beat. Revenue growth stepped down from 56% in the first quarter to 48% and then 39%, while unit growth stayed in the fifties, and every point of price decline has to be re-earned through volume or cost. That is why the release credits favorable product mix and improved cost of production for holding gross margin at 83.9% as reported.

The raise looks enormous until you subtract. Nine-month revenue was $67.2 billion, so the new $91.0–$92.0 billion range implies a fourth quarter of roughly $24.3 billion at the midpoint — flat against Q3's $24.4 billion and about 26% above the $19.3 billion booked in the fourth quarter of 2025. Management raised the year because the quarter was real, not because the next quarter is bigger.

If price is the toll paid to move units, the useful question is who keeps the toll. Not the manufacturer: distribution revenue tracks dollars, not units, and the dollars per script are falling. McKesson reported $15 billion of GLP-1 distribution revenue in its fiscal first quarter ended June 30, 2026, up 24% year over year and 13% sequentially — a strong number that still runs at less than half the rate of Lilly's 53% volume growth.

On the same day, Eli Lilly told the market what a GLP-1 script is worth when supply is the binding constraint: 15% less worldwide and 29% less outside the US. Novo Nordisk built the oral-first strategy on the opposite bet, that pills rather than injections set the category's price point, and it still holds more than 80% of new-brand oral prescriptions with about 90% of them filled self-pay. Lilly's print is the argument against that: if the incumbent can add 53% volume while cutting price 15%, the marginal script in this class is won with discount.

Novo Nordisk reports nine-month results on November 4, 2026, and Cardinal Health reports fiscal first-quarter results on November 5, 2026. Both will be read against the bar Eli Lilly just set. None of that changes the near-term mechanics: volume is the growth engine, price is the cost of it, and the first two earnings seasons of 2027 are where that trade-off shows up in margin rather than in revenue.

One to three years out, the risk inverts. Novo Nordisk's plan to serve ten times more people on oral GLP-1 by 2030, from about 1.5 million today, arrives into a category that Eli Lilly is already pricing down 15% a year. The same squeeze reaches the device layer, where oral obesity medications already account for about 30% of the obesity market. Capacity added into deflation destroys value rather than creating it, and that is the risk the third-quarter print put a number on.